On the morning of June 16, 2026, a delegation of officials—including Xu Yan, Director of the Biopharmaceutical Division of the Ningbo Municipal Bureau of Economy and Information Technology, Lu Zhanpeng, Deputy Director of the Division, and Dai Qiaomin, Deputy Director of the Ninghai County Bureau of Economy and Information Technology—visited Zhejiang Tianyuan Biotechnology Co., Ltd. for on-site research and guidance. This visit also drew keen attention from the capital market, with participation from financial sector representatives including Ningbo Yongyuan Investment Fund, Shanghai Dotone Capital (道彤资本)， as well as the investment banking departments of Bank of Ningbo, the Agricultural Bank of China Ningbo Branch, and the Industrial and Commercial Bank of China Ningbo Branch. Huang Bisheng, Chairman of Tianyuan Biotechnology, Zhu Youwu, Group Chief Administrative Officer, and Jiao Mingming, General Manager, together with the core expert team, warmly received the visiting guests.

      The delegation first toured the company's science and technology exhibition hall. The hall systematically traces the policy evolution of the biopharmaceutical industry over the years, vividly presenting the macro background of industry development and the course of technological progress. Meanwhile, through detailed company introductions and product portfolio displays, the visiting leaders and experts gained a comprehensive understanding of Tianyuan Biotechnology's development strategy, technology platform layout, and core product lines. This all-around presentation—spanning from macro policies to micro-level products—vividly demonstrated the company's deep insight into industry trends and its solid business foundation, leaving a profound impression on the delegation.

      Subsequently, the two sides held a special symposium. At the meeting, General Manager Jiao Mingming first gave a detailed exposition of the company's overall business plan, clearly outlining the company's future strategic path and market vision. Zhu Youwu, Group Chief Administrative Officer, stated that while steadily advancing technological R&D, Tianyuan Biotechnology attaches great importance to building its intellectual property portfolio and its industry-academia-research cooperation ecosystem, and has already formed multidimensional core competitiveness.

      Chairman Huang Bisheng highlighted the company's current internationally leading advantages in iPS cell technology, emphasizing the key role of technological innovation in driving industrial upgrading. He stated: "iPS cell technology is a rising star in the field of regenerative medicine. Tianyuan Biotechnology has built internationally competitive technical barriers in this field. We have not only achieved independent control over core technologies, but also made breakthrough progress at the level of industrialization applications. Going forward, we will continue to increase R&D investment and promote the implementation of iPS cell technology in more clinical scenarios." Following this, Dr. Chen Junjie provided supplementary remarks on the breakthroughs of iPS cells at the level of R&D innovation, while Dr. Liu Guangcheng shared in-depth insights on innovation achievements in cell culture technology. The expert team's professional presentations fully showcased Tianyuan Biotechnology's hardcore strength and forward-looking vision in technological R&D.

      This visit was not only a valuable opportunity for government-enterprise engagement, but also a deep dialogue between capital and industry. Representatives from government authorities, industrial funds, and major banks spoke highly of Tianyuan Biotechnology's technical barriers, business model, and industry development trends. The attending leaders and experts noted that Tianyuan Biotechnology's layout in the iPS cell field aligns with the national development direction of the biopharmaceutical industry and holds great growth potential and investment value.

      This multi-party joint inspection not only strengthened government departments' understanding of and support for the company's development, but also laid a solid foundation for the company's upcoming financing work. In the future, Tianyuan Biotechnology will continue to uphold its innovation-driven development strategy and, with the care of leaders at all levels and the empowerment of capital, accelerate the translation of scientific and technological achievements, contributing to the development of the biopharmaceutical industry in Ningbo and across the nation.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a platform-based biopharmaceutical enterprise driven by AI + iPSC technology and dedicated to developing drugs for heart failure treatment. With its iPS seed cell bank, tumor cell bank, and HLA compatibility matching system as cornerstones, the company has built a full-chain R&D platform covering cell reprogramming, disease model construction, and candidate drug validation. Leveraging the policy advantages of Hainan's "Medical Special Zone," the company has opened up the "last mile" of clinical translation; through its regional network of facilities, it has achieved integrated operations spanning collection, preparation, R&D, and application; and with a closed-loop marketing ecosystem, it connects medical institutions, research platforms, and end users.